Technical Analysis for IOVA - Iovance Biotherapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
IOVA closed up 0.64 percent on Friday, January 18, 2019, on 56 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
|Weak or Absent||Down||Up||Flat|
|See historical IOVA trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||Narrow Range Bar||Range Contraction||0.00%|
|Jan 18||NR7||Range Contraction||0.00%|
|Jan 18||NR7-2||Range Contraction||0.00%|
|Jan 17||50 DMA Support||Bullish||0.64%|
|Jan 17||Narrow Range Bar||Range Contraction||0.64%|
|Jan 17||NR7||Range Contraction||0.64%|
|Jan 16||Shooting Star Candlestick||Bearish||1.18%|
|Jan 15||Crossed Above 50 DMA||Bullish||0.00%|
|Jan 15||180 Bullish Setup||Bullish Swing Setup||0.00%|
|Jan 14||Fell Below 50 DMA||Bearish||4.43%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more IOVA news...
|52 Week High||19.9|
|52 Week Low||7.26|
|200-Day Moving Average||12.57|
|50-Day Moving Average||9.2308|
|20-Day Moving Average||9.055|
|10-Day Moving Average||9.401|
|Average True Range||0.6528|
|Chandelier Exit (Long, 3 ATRs )||8.3416|
|Chandelier Exit (Short, 3 ATRs )||9.2184|
|Upper Bollinger Band||10.1724|
|Lower Bollinger Band||7.9376|
|Percent B (%b)||0.66|
|MACD Signal Line||-0.0025|
|Market Cap||673.79 Million|
|Num Shares||71.5 Million|
|Price-to-Earnings (P/E) Ratio||-4.53|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||9.80|
|Resistance 3 (R3)||9.79||9.67||9.73|
|Resistance 2 (R2)||9.67||9.57||9.67||9.71|
|Resistance 1 (R1)||9.54||9.51||9.61||9.55||9.69|
|Support 1 (S1)||9.29||9.32||9.36||9.30||9.15|
|Support 2 (S2)||9.17||9.26||9.17||9.13|
|Support 3 (S3)||9.04||9.17||9.11|
|Support 4 (S4)||9.05|